Skip to main content
Premium Trial:

Request an Annual Quote

Eisai Gains Access to Forma's Drug Screening Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eisai and Forma Therapeutics on Wednesday announced a collaboration for use of Forma's screening technology to support new drug development in Eisai's pipeline.

Under the terms of the deal, the US subsidiary of Japanese drug manufacturer Eisai, will have non-exclusive access to Forma's Diversity Oriented Synthesis chemistry-generated compound library and cell-based screening platforms. Eisai also has a technology transfer option for Forma's cell-based screening platform.

In return, Forma will receive upfront payments and committed funding of $20 million over three years. It is also eligible for milestone payments and royalties on future products that Eisai commercializes based on the partnership.

In a statement, Steven Tregay, CEO of Cambridge, Mass.-based Forma, said the agreement provides the firm with "significant, additional financial flexibility to pursue our internal drug discovery and development programs in oncology."

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.